Pancreatic Adenocarcinoma Producing Parathyroid Hormone-Related Protein by Reiko Yamada, Kyosuke Tanaka, Hiroyuki Inoue, Takashi Sakuno, Tetsuro Harada, Naohiko Yoshizawa, Hiroshi Miura, Toshihumi Takeuchi, Misaki Nakamura, Masaki Katsurahara, Yasuhiko Hamada, Noriyuki Horiki, Yoshiyuki Takei

“…Forty-five days after initiating chemotherapy, she was readmitted because of a neuropsychiatric disturbance and hypercalcemia. …”
Get full text

PET CT Imaging with FDG in the Therapeutical Management of Locally Advanced Cervical Cancer Diagnosed in a 43-Year-Old Patient: Case Report and Review of the Literature by Ottó Molnar, Simona Mihuțiu, Oreste Mihai Straciuc, Alexandra Vesa, Liviu Lazar

“…Radio-chemotherapy was performed, as well as periodic imaging assessments with a CT of the chest, pelvis, and abdomen, without local and distant relapse. …”
Get full text

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer by Woraporn Sinsuwan, Phawit Norchai

“…Recurrent platinum-resistant clear-cell ovarian cancer has a low overall survival duration of 7-8 months, making it a fatal disease. Currently, chemotherapy is the major kind of treatment, but it offers little advantage. …”
Get full text

Liposarcoma of the Nasopharynx: Diagnosis and Management of a Rare Diagnostic Entity by George X. Papacharalampous, Dimitrios Kikidis, Alexios Vasileiou, Aggeliki Bousiotou, Aristeidis Chrysovergis

“…The role of adjuvant or neoadjuvant chemotherapy still remains controversial.…”
Get full text

Laparoscopic Resection of a Left Upper Quadrant Mass Leading to a Surprise Diagnosis by Hugo J. R. Bonatti, Reinhardt O. Sahmel, Rodrigo B. Erlich

“…In our patient, this seems to have been triggered by chemotherapy for his sarcoma resulting in extramedullary hemopoiesis. …”
Get full text

Primary Dural Spinal Lymphoma Presentation of a Rare Spinal Tumor Case by Dilber Ayçiçek Çeçen, Necati Tatarlı, Hikmet Turan Süslü, Selçuk Özdoğan, Nagehan Özdemir Barışık

“…Following surgery, he received radiotherapy combined with chemotherapy. He experienced a good outcome after four years. …”
Get full text

FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms by Manish Kumar, Abhishek Singh Sengar, Anushree Lye, Pranesh Kumar, Sukhes Mukherjee, Dinesh Kumar, Priyadip Das, Suvro Chatterjee, Adele Stewart, Biswanath Maity

“…Cardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in the pathogenesis of chemotherapy-associated cardiomyopathy. …”
Get full text

Correlations of Cancer-Related Fatigue with Clinicopathological Features and Quality of Life in Gastric Cancer by Dong Liu, A-Dong Xia, Yue-Long Xing, Kai Zhang, Dan Chen

“…At 3 months of follow-up, a comparison of the average CRF BFI scores with those before chemotherapy revealed a decrease in the SD and PR groups and an increase in the PD group. …”
Get full text

Clinical Features, Endoscopic Findings, and Predictive Factors for Mortality in Tissue-Invasive Gastrointestinal Cytomegalovirus Disease between Immunocompetent and Immunocompromis... by Panu Wetwittayakhlang, Natthapat Rujeerapaiboon, Poowadon Wetwittayakhlung, Pimsiri Sripongpun, Nannapat Pruphetkaew, Sawangpong Jandee, Naichaya Chamroonkul, Teerha Piratvisuth

“…Patients with HIV infection, malignancy, or receiving immunosuppressive agents (chemotherapy, high dose, or long-term corticosteroids) were defined as the immunocompromised group. …”
Get full text

Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC by Chao Liu, Yanjuan Chen, Xiaohui Li, Zhijie Bai, Meilin Jiang, Dongsheng Sheng, Wenxue Zou, Rui Huang, Qingyu Huang, Fuhao Wang, Jingyang Zhu, Huiru Sun, Bing Liu, Zongcheng Li, Bing Sun

“…Abstract Background Stereotactic ablative radiotherapy (SABR) is thought to activate T cell responses in patients with cancer, leading to its combination with immunotherapy and chemotherapy for treatment of non-small-cell lung cancer (NSCLC). …”
Get full text

Delayed Intraperitoneal Catheter Erosion into the Small Bowel by Lauren Kerwin, Sean Calhoun

“…Intraperitoneal chemotherapy can be provided in cases of metastatic ovarian carcinoma. …”
Get full text

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases by Ingolf Molle, Irma Petruskevicius, Peter Kamper, Francesco d’Amore

“…Combining daratumumab with chemotherapy may have a role in relapsing T lymphoblastic leukemia/lymphoma.…”
Get full text

Early T-Cell Precursor Leukemia Has a Higher Risk of Induction-Related Infection among T-Cell Acute Lymphoblastic Leukemia in Adult by Kangyu Huang, Min Dai, Qiuli Li, Nannan Liu, Dainan Lin, Qiang Wang, Xuan Zhou, Zhixiang Wang, Ya Gao, Hua Jin, Xiaoli Liu, Qifa Liu, Hongsheng Zhou

“…However, the reports regarding risk factors of induction-related infection are roughly unknown/limited in adult T-ALL during induction chemotherapy. Methods. We performed a retrospective cohort study for the prevalence and risk predictors of induction-related infection among consecutive T-ALL patients (N=97) enrolled in a PDT-ALL-LBL clinical trial. …”
Get full text

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 by Joo Young Jung, Min-Hee Ryu, Baek-Yeol Ryoo, Boram Han, Ji Woong Cho, Man Sup Lim, Hyun Lim, Ho Suk Kang, Min-Jeong Kim, Hong Il Ha, Hunho Song, Jung Han Kim, Hyeong Su Kim, Yoon-Koo Kang, Dae Young Zang

“…Conclusion. FOLFIRI/IFL chemotherapy showed modest antitumour activity and tolerable toxicities in DS/DOS-treated MGC patients.…”
Get full text

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases by Karin Mayer, Selina Kiry, Anna Yordanova, Hojjat Ahmadzadehfar, Florian C. Gaertner, Ralph A. Bundschuh, Markus Essler, Maria A. Gonzalez-Carmona, Christian P. Strassburg, Hanno Matthaei, Philipp Lingohr, Savita Bisht, Peter Brossart, Georg Feldmann

“…Peptide receptor radionuclide therapy (PRRT) and cytostatic chemotherapy were the second most common options, with PRRT being used more frequently in NET G1 and G2 and chemotherapy in NEC G3. …”
Get full text

Self-Perceived Barriers to Pediatric Cancer Care in Sub-Saharan Africa: A Cross-Sectional Multinational Study by Ole Stoeter, Nikolaus C.S. Mezger, Tamara Koenig, Eric Chokunonga, Girum Tessema, Adugna Fekadu Damise, Alda Stevy Makouanzi, Esther Majaliwa, Mahine Ivanga, Bakarou Kamate, Franck Gnahatin, Sarah Nambooze, Ima-Obong A. Ekanem, Toralf Bernig, Biying Liu, Sumit Gupta, Eva Johanna Kantelhardt

“…A questionnaire was administered asking families about self-perceived barriers accessing surgery, radiotherapy, and chemotherapy. To assess associated factors, we conducted a multivariable regression analysis presenting the results as odds ratios (ORs).RESULTSA total of 224 patients with CC was included. …”
Get full text

Impact of Clinical Characteristics and Treatment on Cholangiocarcinoma Prognosis in Southern Thailand by Chirawadee Sathitruangsak, Tanawat Pattarapuntakul, Apichat Kaewdech, Tortrakoon Thongkan, Apinya Prisutkul, Phatcharaporn Thongwatchara, Hutcha Sriplung, Chanon Kongkamol, Kanyanatt Kanokwiroon, Sumalee Obchoei, Pimsiri Sripongpun

“…Unresectable CCA patients with systemic chemotherapy and palliative biliary drainage had better survival rates.…”
Get full text

Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer by Rami Yanes MD, Turcin Saridogan MD, PhD, Vikram Gorantla MD, Abigail Overacre PhD, Ronan W. Hsieh MD, James Celebrezze MD, Tara Magge MD, Meghana Singhi MD, Anwaar Saeed MD, Amer H. Zureikat MD, Arvind N. Dasari MD, Ibrahim Halil Sahin MD

“…The management of early-stage colon cancer involves surgical resection of the primary tumor with or without chemotherapy, depending on pathological staging. The benefit of adjuvant chemotherapy for stage II and III colon cancer is approximately 5% and 15%, indicating the need for optimization for risk stratification and patient selection. …”
Get full text

The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer by Gaia Passarella, Stefania Canova, Maria Ida Abbate, Giulia Caspani, Luca Sala, Alessandro Russo, Paola Muscolino, Francesca Colonese, Diego Luigi Cortinovis

“…So far, the neo-adjuvant chemotherapy strategies have led to a small benefit with an improvement of 5% in overall survival as an absolute benefit. …”
Get full text

A 26-Year-Old Male with Mesothelioma Due to Asbestos Exposure by P. Zarogoulidis, M. Orfanidis, T. C. Constadinidis, E. Eleutheriadou, T. Kontakiotis, T. Kerenidi, L. Sakkas, N. Courcoutsakis, K. Zarogoulidis

“…The patient was not a candidate for surgery, and chemotherapy treatment was initiated. While patient's chemotherapy is still ongoing, no other similar cases of students or teachers have been traced up to date from his school. …”
Get full text